Mount Sinai Dermatologists Use Tape Strips to Map Immune Changes in Common Skin Disease
New Way to Study Skin: No Needles, Just Tape
Doctors from the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai have found a new way to study seborrheic dermatitis (SD), a common skin condition that causes itchy, red, and flaky skin, especially on the scalp, face, and chest.
According to their research, published in the June issue of Journal of the American Academy of Dermatology, the Mount Sinai team used sticky tape—rather than a painful biopsy—to collect skin cells from 28 adults with seborrheic dermatitis. Dermatologists have used tape stripping for other conditions for years, but this is the first time it has been applied to identify immune and lipid changes in patients with SD.
The special tape works a bit like a sticky note—it gently pulls off the top layer of skin without hurting the patient. When scientists look closely at what is on the tape, they can see tiny clues about what is happening under the surface.
In this study, they found that certain immune signals, called interleukins, were very active in the skin of people with seborrheic dermatitis. Interleukins are a type of cytokine, a group of proteins that act as chemical messengers between cells, particularly white blood cells, to regulate immune responses. These signals can cause the body to overreact and create inflammation.
The researchers found that the changes in the immune systems of people with seborrheic dermatitis are similar to those in people with psoriasis, another skin condition, but also have their own special patterns. This is the largest transcriptomic study (study of the full range of messenger RNA) to date on seborrheic dermatitis.
“Seborrheic dermatitis is a common and chronic inflammatory skin disease that causes itching and scaling on the face, scalp, chest, and skin folds, affecting up to 5 percent of adults,” says lead author Emma Guttman-Yassky, MD, PhD, Waldman Professor and Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. “We were able to analyze the molecular skin profile of adult patients with SD using tape strips. Until now, our understanding of the disease has been limited because studying it required invasive skin biopsies. This is the largest transcriptomic study to date on seborrheic dermatitis, and for the first time, we were able to use simple, minimally invasive tape strips to uncover the immune pathways driving the disease—specifically interleukin 23, T-helper 17, and T-helper 22 responses. This breakthrough opens the door to developing more targeted, effective treatments for patients.”
Right now, many people with this skin condition use creams that can have side effects. This new research gives hope for new medicines that could help people feel better faster, with fewer risks.
"Tape strips are less invasive than biopsies, which are the gold standard but can be painful and intrusive, making them less than ideal for young or sensitive patients,” said Benjamin Ungar, MD, Director of the Alopecia Center of Excellence and Director of the Rosacea and Seborrheic Dermatitis Clinic at the Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai. “This new research is exciting because we used a noninvasive method (tape) to identify unique immune responses, and that will allow us to better understand seborrheic dermatitis."
Dr. Guttman and Dr. Ungar led a team from various national and international institutions. Arcutis Biotherapeutics, Inc., helped fund this research. With support from the Icahn School of Medicine Clinical Translational Science Award (UL1TR004419) TL-1 program.
To read the full manuscript and see the full list of contributors visit: https://www.jaad.org/article/S0190-9622(25)00180-X/fulltext
To learn more about Mount Sinai’s Depart of Dermatology visit: https://www.mountsinai.org/dermatology
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.